Use of Period Analysis to Timely Assess Five-Year Relative Survival for Patients with Ovarian Cancer from Taizhou, Eastern China
Abstract
1. Introduction
2. Materials and Methods
2.1. Data Sources
2.2. Statistical Analysis
3. Results
3.1. Basic Information for Patients with Ovarian Cancer
3.2. Five-Year RS of Ovarian Cancer Patients during 2014–2018
3.3. Five-Year RS Trends during 2004–2018
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Khazaei, Z.; Namayandeh, S.M.; Beiranvand, R.; Naemi, H.; Bechashk, S.M.; Goodarzi, E. Worldwide incidence and mortality of ovarian cancer and Human Development Index (HDI): GLOBOCAN sources and methods 2018. J. Prev. Med. Hyg. 2021, 62, E174–E184. [Google Scholar] [CrossRef] [PubMed]
- Razi, S.; Ghoncheh, M.; Mohammadian-Hafshejani, A.; Aziznejhad, H.; Mohammadian, M.; Salehiniya, H. The incidence and mortality of ovarian cancer and their relationship with the Human Development Index in Asia. Ecancermedicalscience 2016, 10, 628. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Saba, S.; Gill, P.K. Global Scenario on Ovarian Cancer—Its Dynamics, Relative Survival, Treatment, and Epidemiology. Adesh Univ. J. Med. Sci. Res. 2020, 2, 17–25. [Google Scholar]
- Oberaigner, W.; Minicozzi, P.; Bielska-Lasota, M.; Allemani, C.; De Angelis, R.; Mangone, L.; Santaquilani, M. Eurocare Working Group Survival for Ovarian Cancer in Europe: The across-country variation did not shrink in the past decade. Acta Oncol. 2012, 51, 441–453. [Google Scholar] [CrossRef]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clinic. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Tang, Z.; Deng, M.; Yu, C.; Liu, Q. Current Status and Trend Analysis of Ovarian Cancer Disease Burden in China. J. Int. Obstet. Gynecol. 2022, 49, 222–227. [Google Scholar]
- Reid, B.M.; Permuth, J.B.; Sellers, T.A. Epidemiology of Ovarian Cancer: A Review. Cancer Biol. Med. 2017, 14, 9. [Google Scholar]
- Allemani, C.; Weir, H.K.; Carreira, H.; Harewood, R.; Spika, D.; Wang, X.-S.; Bannon, F.; Ahn, J.V.; Johnson, C.J.; Bonaventure, A.; et al. Global Surveillance of Cancer Survival 1995–2009: Analysis of Individual Data for 25,676,887 Patients from 279 Population-Based Registries in 67 Countries (Concord-2). Lancet 2015, 385, 977–1010. [Google Scholar] [CrossRef][Green Version]
- Timmermans, M.; Sonke, G.; Van de Vijver, K.K.; van der Aa, M.A.; Kruitwagen, R.F.P.M. No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. Eur. J. Cancer 2018, 88, 31–37. [Google Scholar] [CrossRef]
- Åkeson, M.; Jakobsen, A.-M.; Zetterqvist, B.-M.; Holmberg, E.; Brännström, M.; Horvath, G. A Population-Based 5-Year Cohort Study Including All Cases of Epithelial Ovarian Cancer in Western Sweden: 10-Year Survival and Prognostic Factors. Int. J. Gynecol. Cancer 2009, 19. [Google Scholar] [CrossRef]
- Brenner, H.; Gefeller, O.; Hakulinen, T. Period Analysis for ‘up-to-Date’ cancer Survival Data: Theory, Empirical Evaluation, Computational Realisation and Applications. Eur. J. Cancer 2004, 40, 326–335. [Google Scholar] [CrossRef] [PubMed]
- Brenner, H. Long-Term Survival Rates of Cancer Patients Achieved by the End of the 20th Century: A Period Analysis. Lancet 2002, 360, 1131–1135. [Google Scholar] [CrossRef] [PubMed]
- Arndt, V.; Lacour, B.; Steliarova-Foucher, E.; Spix, C.; Znaor, A.; Pastore, G.; Stiller, C.; Brenner, H. Up-to-Date Monitoring of Childhood Cancer Long-Term Survival in Europe: Tumours of the Sympathetic Nervous System, Retinoblastoma, Renal and Bone Tumours, and Soft Tissue Sarcomas. Ann. Oncol. 2007, 18, 1722–1733. [Google Scholar] [CrossRef] [PubMed]
- Brenner, H.; Söderman, B.; Hakulinen, T. Use of Period Analysis for Providing More up-to-Date Estimates of Long-Term Survival Rates: Empirical Evaluation among 370 000 Cancer Patients in Finland. Int. J. Epidemiol. 2002, 31, 456–462. [Google Scholar] [CrossRef] [PubMed]
- Jiang, X.; Wang, L.; Cheng, Y.; Tang, H.; Chen, T. Assessment of long-term survival of cancer patients using cancer registry data from eastern China: Period analysis is superior to traditional methods. Int. J. Cancer 2020, 147, 996–1005. [Google Scholar] [CrossRef]
- Gong, W.; Luo, S.; Hu, R.; Wang, H.; Pan, J.; Fei, F.; He, Q.; Yu, M. Analysis of Survival Rate of Breast, Cervical, and Ovarian Cancer Patients during 2005–2010 in Zhejiang Province, China. Chin. J. Prev. Med. 2014, 48, 366–369. [Google Scholar]
- Gondos, A.; Brenner, H.; Holleczek, B. periodR–an R Package to Calculate Long-term Cancer Survival Estimates Using Period Analysis. Methods Inf. Med. 2009, 48, 123–128. [Google Scholar] [CrossRef]
- Zeng, H.; Chen, W.; Zheng, R.; Zhang, S.; Ji, J.S.; Zou, X.; Xia, C.; Sun, K.; Yang, Z.; Li, H.; et al. Changing cancer survival in China during 2003–15: A pooled analysis of 17 population-based cancer registries. Lancet Glob. Health 2018, 6, e555–e567. [Google Scholar] [CrossRef][Green Version]
- Tseng, J.H.; Cowan, R.A.; Zhou, Q.; Iasonos, A.; Byrne, M.; Polcino, T.; Polen-De, C.; Gardner, G.J.; Sonoda, Y.; Zivanovic, O. Continuous Improvement in Primary Debulking Surgery for Advanced Ovarian Cancer: Do Increased Complete Gross Resection Rates Independently Lead to Increased Progression-Free and Overall Survival? Gynecol. Oncol. 2018, 151, 24–31. [Google Scholar] [CrossRef]
- Rauh-Hain, J.; Alexander Melamed, A.; Wright, A.; Gockley, A.; Clemmer, J.T.; Schorge, J.O.; Del Carmen, M.G.; Keating, N.L. Overall Survival following Neoadjuvant Chemotherapy Vs Primary Cytoreductive Surgery in Women with Epithelial Ovarian Cancer: Analysis of the National Cancer Database. JAMA Oncol. 2017, 3, 76–82. [Google Scholar] [CrossRef][Green Version]
- Kuroki, L.; Guntupalli, S.R. Treatment of Epithelial Ovarian Cancer. BMJ 2020, 371, m3773. [Google Scholar] [CrossRef] [PubMed]
- Shin, D.W.; Bae, J.; Ha, J.; Jung, K.-W. Conditional Relative Survival of Ovarian Cancer: A Korean National Cancer Registry Study. Front. Oncol. 2021, 11, 639839. [Google Scholar] [CrossRef] [PubMed]
- Menon, U.; Karpinskyj, C.; Gentry-Maharaj, A. Ovarian Cancer Prevention and Screening. Obstet. Gynecol. 2018, 131, 909–927. [Google Scholar] [CrossRef][Green Version]
- Wu, J.; Sun, H.; Yang, L.; Deng, Y.; Yan, Y.; Wang, S.; Yang, G.; Ma, H. Improved survival in ovarian cancer, with widening survival gaps of races and socioeconomic status: A period analysis, 1983–2012. J. Cancer 2018, 9, 3548–3556. [Google Scholar] [CrossRef]
- Wang, Y.; Du, L.; Li, H.; Zhu, C.; Zhou, H. Survey on Awareness of Cancer Prevention in Residents of Zhejiang Province. China Cancer 2018, 27, 921–925. [Google Scholar]
- Stewart, S.L.; Harewood, R.; Matz, M.; Rim, S.H.; Sabatino, S.A.; Ward, K.C.; Weir, H.K. Disparities in ovarian cancer survival in the United States (2001–2009): Findings from the CONCORD-2 study. Cancer 2017, 123, 5138–5159. [Google Scholar] [CrossRef]
- Goldstein, C.; Susman, E.; Lockwood, S.; Medlin, E.; Behbakht, K. Awareness of Symptoms and Risk Factors of Ovarian Cancer in a Population of Women and Healthcare Providers. Clin. J. Oncol. Nurs. 2015, 19, 206–212. [Google Scholar] [CrossRef][Green Version]
- Villanueva, C.; Chang, J.; Ziogas, A.; Bristow, R.E.; Vieira, V.M. Ovarian Cancer in California: Guideline Adherence, Survival, and the Impact of Geographic Location, 1996–2014. Cancer Epidemiol. 2020, 69, 101825. [Google Scholar] [CrossRef]
- Eskander, R.N.; Carpenter, B.A.; Wu, H.G.; Wolf, J.K. The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients. Curr. Med. Res. Opin. 2016, 32, 1161–1165. [Google Scholar] [CrossRef]
- Zeng, C.; Wen, W.; Morgans, A.K.; Pao, W.; Shu, X.-O.; Zheng, W. Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results from the National Cancer Institute Surveillance, Epidemiology, and End Results (Seer) Program in the United States, 1990 to 2010. JAMA Oncol. 2015, 1, 88–96. [Google Scholar] [CrossRef][Green Version]
- Matsuda, A.; Katanoda, K. Five-Year Relative Survival Rate of Ovarian Cancer in the USA, Europe and Japan. Jpn. J. Clin. Oncol. 2014, 44, 196. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Athey, R.A.; Macdonald, M.C.; Jha, S. Stage of Ovarian Cancer at Diagnosis. Does Presentation as an Emergency Make a Difference? Eur. J. Obstet. Gynecol. Reprod. Biol. 2021, 261, 7–11. [Google Scholar] [CrossRef] [PubMed]
- Chen, T.; Jansen, L.; Gondos, A.; Emrich, K.; Holleczek, B.; Katalinic, A.; Luttmann, S.; Meyer, M.; Brenner, H. Survival of Ovarian Cancer Patients in Germany in the Early 21st Century: A Period Analysis by Age, Histology, Laterality, and Stage. Eur. J. Cancer Prev. 2013, 22, 59–67. [Google Scholar] [CrossRef] [PubMed]
- Schuurman, M.; Kruitwagen, R.; Portielje, J.; Roes, E.; Lemmens, V.; van der Aa, M. Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis. Gynecol. Oncol. 2018, 149, 270–274. [Google Scholar] [CrossRef] [PubMed]
- Cai, Y.; Chen, W.; Wang, X.; Xia, X.; Cui, X.; Wu, S.; Li, J. Contemporary trends on expenditure of hospital care on total cancer and its subtypes in China during 2008−2017. Chin. J. Cancer Res. 2021, 33, 627–636. [Google Scholar] [CrossRef]
- Colombo, N.; Van Gorp, T.; Parma, G.; Amant, F.; Gatta, G.; Sessa, C.; Vergote, I. Ovarian Cancer. Crit. Rev. Oncol. Hematol. 2006, 60, 159–179. [Google Scholar] [CrossRef]
- Gupta, K.K.; Gupta, V.; Naumann, R.W. Ovarian cancer: Screening and future directions. Int. J. Gynecol. Cancer 2019, 29, 195–200. [Google Scholar] [CrossRef]
- Menon, U.; Gentry-Maharaj, A.; Burnell, M.; Singh, N.; Ryan, A.; Karpinskyj, C.; Carlino, G.; Taylor, J.; Massingham, S.K.; Raikou, M.; et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet 2021, 397, 2182–2193. [Google Scholar] [CrossRef]
- Choi, Y.-H.; Terry, M.B.; Daly, M.B.; MacInnis, R.J.; Hopper, J.L.; Colonna, S.; Buys, S.S.; Andrulis, I.L.; John, E.M.; Kurian, A.W.; et al. Association of Risk-Reducing Salpingo-Oophorectomy with Breast Cancer Risk in Women with BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncol. 2021, 7, 585–592. [Google Scholar] [CrossRef]
- Ivanov, S.; Batashki, I. Five years survival in patients with endometrioid ovarian cancer versus patients with serous ovarian cancer. Akush Ginekol. 2008, 47, 9–11. [Google Scholar]
- Gaitskell, K.; Hermon, C.; Barnes, I.; Pirie, K.; Floud, S.; Green, J.; Beral, V.; Reeves, G.K.; Million Women Study Collaborators. Ovarian Cancer Survival by Stage, Histotype, and Pre-Diagnostic Lifestyle Factors, in the Prospective UK Million Women Study. Cancer Epidemiol. 2022, 76, 102074. [Google Scholar] [CrossRef] [PubMed]
Characteristics | Number of Cases (%) | Diagnosed Interval | χ2 | p | ||
---|---|---|---|---|---|---|
2004–2008 (%) | 2009–2013 (%) | 2014–2018 (%) | ||||
Total | 770 (100) | 53 (100) | 290 (100) | 427 (100) | ||
Region | ||||||
Urban area | 185 (24.0) | 25 (47.2) | 78 (26.9) | 82 (19.2) | ||
Rural area | 585 (76.0) | 28 (52.8) | 212 (73.1) | 345 (80.8) | 22.301 | <0.0001 |
Average age (years) | 54.4 | 57.9 | 55.8 | 53.2 | ||
Age at diagnosis (years) | ||||||
<55 | 174 (22.6) | 9 (17.0) | 68 (23.4) | 97 (22.7) | ||
55~64 | 164 (21.3) | 10 (18.9) | 63 (21.7) | 91 (21.3) | 4.858 | 0.5621 |
65~74 | 196 (25.5) | 14 (26.4) | 81 (27.9) | 101 (23.7) | ||
>74 | 236 (30.6) | 20 (37.7) | 78 (26.9) | 138 (32.3) |
Estimated Value (%) | Standard Error (SE) | |
---|---|---|
Total | 69.2 | 1.8 |
Age at diagnosis (years) | ||
<55 | 79.6 | 3.6 |
55~64 | 72.9 | 3.0 |
65~74 | 68.4 | 2.8 |
>74 | 66.9 | 2.3 |
Region | ||
Urban area | 77.5 | 3.6 |
Rural area | 64.9 | 2.4 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bing, X.; Lei, H.; Zhao, X.; Cheng, Y.; Wang, L.; Yang, J.; Xu, M.; Yu, C.; Chen, T. Use of Period Analysis to Timely Assess Five-Year Relative Survival for Patients with Ovarian Cancer from Taizhou, Eastern China. J. Clin. Med. 2023, 12, 3480. https://doi.org/10.3390/jcm12103480
Bing X, Lei H, Zhao X, Cheng Y, Wang L, Yang J, Xu M, Yu C, Chen T. Use of Period Analysis to Timely Assess Five-Year Relative Survival for Patients with Ovarian Cancer from Taizhou, Eastern China. Journal of Clinical Medicine. 2023; 12(10):3480. https://doi.org/10.3390/jcm12103480
Chicago/Turabian StyleBing, Xin, Huijun Lei, Xiaojiao Zhao, Yongran Cheng, Liangyou Wang, Jun Yang, Mingzhi Xu, Chenhuan Yu, and Tianhui Chen. 2023. "Use of Period Analysis to Timely Assess Five-Year Relative Survival for Patients with Ovarian Cancer from Taizhou, Eastern China" Journal of Clinical Medicine 12, no. 10: 3480. https://doi.org/10.3390/jcm12103480
APA StyleBing, X., Lei, H., Zhao, X., Cheng, Y., Wang, L., Yang, J., Xu, M., Yu, C., & Chen, T. (2023). Use of Period Analysis to Timely Assess Five-Year Relative Survival for Patients with Ovarian Cancer from Taizhou, Eastern China. Journal of Clinical Medicine, 12(10), 3480. https://doi.org/10.3390/jcm12103480